(Total Views: 1569)
Posted On: 09/26/2017 2:09:04 PM
Post# of 229
NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Provides Update on Advancements of Proprietary Biosynthesis Technology
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning provided an update to its investors on the significant advancements in the development of its proprietary technology for the microbial biosynthesis of cannabinoids. InMed has successfully demonstrated that it can selectively produce all four “gateway” cannabinoids using genetically engineered microorganisms. These molecules can be further functionalized to produce any of the 90+ cannabinoids that occur naturally in the cannabis plant. “Successful scale-up and commercialization of the biosynthesis process for cannabinoid production is a top priority for InMed,” Eric A. Adams, president and CEO of InMed, stated in the news release. “We are dedicating substantial resources to this project and have retained key individuals as we transition into the advanced pilot and to the commercialization phases of development. The breadth and depth of our patents, currently either submitted or being prepared for submission, will provide significant protection to the entire process.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning provided an update to its investors on the significant advancements in the development of its proprietary technology for the microbial biosynthesis of cannabinoids. InMed has successfully demonstrated that it can selectively produce all four “gateway” cannabinoids using genetically engineered microorganisms. These molecules can be further functionalized to produce any of the 90+ cannabinoids that occur naturally in the cannabis plant. “Successful scale-up and commercialization of the biosynthesis process for cannabinoid production is a top priority for InMed,” Eric A. Adams, president and CEO of InMed, stated in the news release. “We are dedicating substantial resources to this project and have retained key individuals as we transition into the advanced pilot and to the commercialization phases of development. The breadth and depth of our patents, currently either submitted or being prepared for submission, will provide significant protection to the entire process.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
